Evidence map›Paper›PMID 29182498›Full record

Trial reportJournal of women's health (2002)2018

Effect of Single-Session, Cryogen-Cooled Monopolar Radiofrequency Therapy on Sexual Function in Women with Vaginal Laxity: The VIVEVE I Trial.

Michael Krychman, Christopher G Rowan, Bruce B Allan, Scott Durbin, Ashley Yacoubian, Deborah Wilkerson

Open access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Journal of women's health (2002), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 7 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 7 syntheses or guidelines pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Mindfulness-based interventions for addressing sexual function after cancer: A systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Pooled it
  3. Vaginal lasers for treating stress urinary incontinence in women.The Cochrane database of systematic reviews · 2025
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Review
  13. Review
  14. Chapter 4.5: New Proposed Treatments for Pelvic Organ Prolapse.International urogynecology journal · 2026
    Review
  15. Article
  16. Prevalence of vaginal laxity in primiparous women six months after birth.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Michael Krychman1 Southern California Center for Sexual Health and Survivorship Medicine , Newport Beach, California.
Christopher G Rowan2 Collaborative Healthcare Research and Data Analytics (COHRDATA) , Santa Monica, California.
Bruce B Allan3 Allan Centre , Calgary, Alberta, Canada .
Scott Durbin4 Viveve Medical, Inc. , Englewood, Colorado.
Ashley Yacoubian4 Viveve Medical, Inc. , Englewood, Colorado.
Deborah Wilkerson4 Viveve Medical, Inc. , Englewood, Colorado.
Viveve (United States) · USBritish Columbia Rehabilitation Foundation · CAQuantum Leap Healthcare Collaborative · USSouthern California Reproductive Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis subanalysis of the VIVEVE I trial aimed to evaluate the impact of cryogen-cooled monopolar radiofrequency (CMRF) therapy, for the treatment of vaginal laxity, on the domains of sexual function included in the Female Sexual Function Index (FSFI). MATERIALS AND

methodsThe VIVEVE I clinical trial was prospective, randomized, single-blind, and Sham-controlled. Nine clinical study centers in Canada, Italy, Spain, and Japan were included. This subanalysis included premenopausal women with self-reported vaginal laxity who had ≥1 term vaginal delivery and a baseline FSFI total score ≤26.5, indicating sexual dysfunction. Enrolled subjects were randomized (2:1) to receive CMRF therapy [Active (90 J/cm

resultsSubjects randomized to Active treatment (n = 73) had greater improvement than Sham subjects (n = 35) on all FSFI domains of sexual function at 6 months postintervention. The analysis of covariance change from baseline analyses showed statistically significant improvements, in favor of Active treatment, for sexual arousal (p = 0.004), lubrication (p = 0.04), and orgasm (p = 0.007). In addition, Active treatment was associated with clinically important and statistically significant improvements in sexual desire [Odds ratio (OR) = 3.01 (1.11-8.17)], arousal [OR = 2.73 (1.06-7.04)], and orgasm [OR = 2.58 (1.08-6.18)].

conclusionsThis subanalysis showed CMRF therapy is associated with statistically significant and clinically important improvements in sexual function in women with vaginal laxity. These findings provide the first randomized, placebo-controlled energy-based device evidence for functional improvements associated with a nonsurgical modality for a highly prevalent and undertreated condition.

Indexed as

PremenopauseRadiofrequency TherapyAdultCanadaDelivery, ObstetricElasticityFemaleHumansItalyJapanMiddle AgedPersonal SatisfactionProspective StudiesSexual Dysfunction, PhysiologicalSingle-Blind MethodSpainFSFIFSFI domainsnonsurgicalradiofrequency therapysexual functionsurface cooledvaginal laxityvaginal looseness

Identifiers

PMID29182498
PMCPMC5865245
OpenAlexW2769618556

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.